Surbhi Jain1, Lijia Xie1, Batbold Boldbaatar1, Selena Y Lin2, James P Hamilton3, Stephen J Meltzer3,4, Shun-Hua Chen5, Chi-Tan Hu6,7, Timothy M Block2, Wei Song1, Ying-Hsiu Su2. 1. JBS Science Inc., Doylestown, Pennsylvania, USA. 2. Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. 3. Division of Gastroenterology and Hepatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA. 5. Department of Microbiology, Medical College, National Cheng Kung University, Tainan, Taiwan, China. 6. Department of Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, China. 7. Tzu Chi University, Hualien, Taiwan, China.
Abstract
AIM: Aberrant methylation of the promoter, P2, and the first exon, E1, regions of the tumor suppressor gene RASSF1A, have been associated with hepatocellular carcinoma (HCC), albeit with poor specificity. This study analyzed the methylation profiles of P1, P2 and E1 regions of the gene to identify the region of which methylation most specifically corresponds to HCC and to evaluate the potential of this methylated region as a biomarker in urine for HCC screening. METHODS: Bisulfite DNA sequencing and quantitative methylation-specific polymerase chain reaction assays were performed to compare methylation of the 56 CpG sites in regions P1, P2 and E1 in DNA isolated from normal, hepatitic, cirrhotic, adjacent non-HCC, and HCC liver tissue and urine samples for the characterization of hypermethylation of the RASSF1A gene as a biomarker for HCC screening. RESULTS: In tissue, comparing HCC (n = 120) with cirrhosis and hepatitis together (n = 70), methylation of P1 had an area under the receiver operating characteristics curve (AUROC) of 0.90, whereas methylation of E1 and P2 had AUROC of 0.84 and 0.72, respectively. At 90% sensitivity, specificity for P1 methylation was 72.9% versus 38.6% for E1 and 27.1% for P2. Methylated P1 DNA was detected in urine in association with cirrhosis and HCC. It had a sensitivity of 81.8% for α-fetoprotein negative HCC. CONCLUSION: Among the three regions analyzed, methylation of P1 is the most specific for HCC and holds great promise as a DNA marker in urine for screening of cirrhosis and HCC. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
AIM: Aberrant methylation of the promoter, P2, and the first exon, E1, regions of the tumor suppressor gene RASSF1A, have been associated with hepatocellular carcinoma (HCC), albeit with poor specificity. This study analyzed the methylation profiles of P1, P2 and E1 regions of the gene to identify the region of which methylation most specifically corresponds to HCC and to evaluate the potential of this methylated region as a biomarker in urine for HCC screening. METHODS:Bisulfite DNA sequencing and quantitative methylation-specific polymerase chain reaction assays were performed to compare methylation of the 56 CpG sites in regions P1, P2 and E1 in DNA isolated from normal, hepatitic, cirrhotic, adjacent non-HCC, and HCC liver tissue and urine samples for the characterization of hypermethylation of the RASSF1A gene as a biomarker for HCC screening. RESULTS: In tissue, comparing HCC (n = 120) with cirrhosis and hepatitis together (n = 70), methylation of P1 had an area under the receiver operating characteristics curve (AUROC) of 0.90, whereas methylation of E1 and P2 had AUROC of 0.84 and 0.72, respectively. At 90% sensitivity, specificity for P1 methylation was 72.9% versus 38.6% for E1 and 27.1% for P2. Methylated P1 DNA was detected in urine in association with cirrhosis and HCC. It had a sensitivity of 81.8% for α-fetoprotein negative HCC. CONCLUSION: Among the three regions analyzed, methylation of P1 is the most specific for HCC and holds great promise as a DNA marker in urine for screening of cirrhosis and HCC. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
Authors: O I Serdyuk; I V Botezatu; V P Shelepov; G I Potapova; R P Alekhina; Y K Molyaka; V S Anan'ev; V I Knysh; O S Melkonyan; S R Umanskii; A V Lichtenshtein Journal: Bull Exp Biol Med Date: 2001-03 Impact factor: 0.804
Authors: Benjamin P Song; Surbhi Jain; Selena Y Lin; Quan Chen; Timothy M Block; Wei Song; Dean E Brenner; Ying-Hsiu Su Journal: J Mol Diagn Date: 2012-01-16 Impact factor: 5.568
Authors: K C Allen Chan; Paul B S Lai; Tony S K Mok; Henry L Y Chan; Chunming Ding; S W Yeung; Y M Dennis Lo Journal: Clin Chem Date: 2008-07-24 Impact factor: 8.327